Cartilage matrix protease inhibition

“Cartilage matrix protease inhibition” refers broadly to strategies aimed at blocking the activity of enzymes—primarily matrix metalloproteinases (MMPs), aggrecanases, collagenases, gelatinases—that are responsible for breaking down key structural proteins within articular cartilage. These degradative enzymes are produced by chondrocytes, synovial cells, and infiltrating leukocytes during joint diseases such as osteoarthritis and rheumatoid arthritis. Excessive activity leads to loss of extracellular matrix integrity, joint dysfunction, pain, and disability. Therapeutic approaches focus on developing small-molecule inhibitors or biologics that selectively block these enzymes' actions while minimizing side effects due to interference with normal tissue remodeling processes[2][3][4]. If you need structured information about individual targets within this category—such as "Matrix metalloproteinase‑13"—please specify the particular enzyme/protein name.

Other names

Cartilage-degrading enzyme inhibitionProtease inhibitor therapy for cartilageInhibition of cartilage matrix metalloproteinases

Drugs act by inhibiting the enzymatic activity of matrix metalloproteinases and other proteases responsible for degrading collagen and aggrecan in articular cartilage[2][3][4].